Cover Image
Market Research Report
Product code 
991361

Rx-to-OTC Switch: A Hot Topic Report

Published: | Nicholas Hall & Company | 171 Pages | Delivery time: 1-2 business days

Price

Back to Top
Rx-to-OTC Switch: A Hot Topic Report
Published: May 26, 2021
Nicholas Hall & Company
Content info: 171 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents

With Switch being one of the crucial growth drivers for the consumer healthcare industry, this hot topic report provides an essential how-to guide to Switch, exploring the key questions you need to answer when planning your own Switch strategy.

Evaluating the core components of what makes a successful Switch, with case studies of successfully Switched brands, make sure you have read this report before you implement your Switch strategy.

TABLE OF CONTENTS

Foreword from Nicholas Hall

The non-prescription imperative

  • Rx-to-OTC switch
  • Why is Rx-to-OTC switch an imperative?
  • The current challenge for CHC
  • Innovation expands reach
  • Non-prescription care avoids
  • unnecessary costs to healthcaresystems
  • Reversing undertreatment essential Cost of ageing populations
  • Europe heavily impacted by NCDs
  • Improving public health and health equity
  • A new commercial opportunity
  • COVID-19 spotlights health Inequities
  • Pandemic cost is immense
  • Pandemic strained ability to care
  • CHC has the means to advance OTC access
  • US FDA taking steps towards interoperability
  • Interoperability connects and co-ordinates processes across the healthcare ecosystem
  • Future labelling strategies can enforce the DFL with features and benefits of interoperability
  • Capabilities of interoperability will unlock complex switches
  • The non-prescription imperative

Switch strategy

  • Switch strategy goals
  • Switch strategy Leadership Team
  • Regulatory and Medical Team
  • Marketing Team
  • Professional Marketing Team
  • Supply Team
  • Go-to-market Team
  • Switch strategy
  • Switch strategy learnings

Drivers & barriers of switch

  • Switch - Drivers
  • Switch - Barriers

Key switch markets

  • USA
  • UK
  • EU - EMA
  • Germany
  • France
  • New Zealand
  • Australia
  • Japan
  • Brazil
  • OTC reimbursement can deter sales

Switch pipeline

  • Switch pipeline overview
  • USA switch forecasts
  • US switch difficult but rewarding PDE5i switches for ED treatment
  • PDE5i sales forecast; leading markets
  • Access to DOC in West behind Asia
  • DOC sales forecast; leading markets
  • Triptan switch has potential in US
  • Other CHC areas to watch
  • CBD - a high potential molecule

Key market switch mechanisms

  • Switch can occur under several models
  • USA switch mechanism
  • UK switch mechanism
  • EU Centralised Procedure switch mechanism
  • New Zealand switch mechanism
  • Australia switch mechanism
  • Japan switch mechanism
  • Brazil switch mechanism
  • OTC exclusivity incentivises switch
  • Inadequate exclusivity periods
  • Switch without exclusivity
  • Reclassifying via scheduling
  • Under-the-counter sales
  • Counterfeit medicines

Cost vs benefit

  • Cost vs benefit
  • Case study: Flonase

Consumers rapidly adopt digital tools

  • Digital benefits the healthcare cycle
  • Consumers already gathering data
  • Health demands from wearables
  • Digital consumer conversations
  • Smartspeaker engagement
  • Interactive audio ads in action
  • Tech innovation for self-care
  • Switching to digital data collection
  • Telehealth booms in pandemic

Test & trace

  • Increased capabilities to remotely test
  • Pros and cons of digital testing
  • Digital test and treat in action
  • Digital testing developments

Marketing learnings

  • Marketing learnings overview
  • Insights from marketing learnings
  • Marketing tactics overview
  • Failed switches
  • Switch successes

Key switches

  • Leading global switches
  • Top 10 global switches
  • Switches are leading brands globally
  • US dominates switch success
  • Top 10 US switches
  • ellaOne (HRA Pharma)
  • Flonase (GSK)
  • Nexium 24HR / Control (GSK)
  • Viagra Connect (Viatris)
  • Sildenafil switch first global in NZ
  • Poland first to switch sildenafil in Europe
  • ED switches on global scale low
  • Alli (GSK)
  • Zocor Heart-Pro (J&J)
  • Flomax (BI; now Sanofi)
  • Oxytrol for Women (Merck / MSD; then Bayer)
  • Voltaren Arthritis Pain (GSK)
  • Pataday (Alcon)

APPENDIX

The public health case

  • QALY loss as a result of pandemic
  • Mental health issues increasing

Reverse switch & restrictions

  • Factors influencing reverse switch
  • Addiction cardio and overdose risks
  • Health risks driven by misuse
  • Reverse switch case study: France
  • Global: restrictions not always effective
  • Steps to be taken by manufacturers

Sources Appendix

TABLE OF CONTENTS

Foreword from Nicholas Hall

The non-prescription imperative

  • Rx-to-OTC switch
  • Why is Rx-to-OTC switch an imperative?
  • The current challenge for CHC
  • Innovation expands reach
  • Non-prescription care avoids
  • unnecessary costs to healthcaresystems
  • Reversing undertreatment essential Cost of ageing populations
  • Europe heavily impacted by NCDs
  • Improving public health and health equity
  • A new commercial opportunity
  • COVID-19 spotlights health Inequities
  • Pandemic cost is immense
  • Pandemic strained ability to care
  • CHC has the means to advance OTC access
  • US FDA taking steps towards interoperability
  • Interoperability connects and co-ordinates processes across the healthcare ecosystem
  • Future labelling strategies can enforce the DFL with features and benefits of interoperability
  • Capabilities of interoperability will unlock complex switches
  • The non-prescription imperative

Switch strategy

  • Switch strategy goals
  • Switch strategy Leadership Team
  • Regulatory and Medical Team
  • Marketing Team
  • Professional Marketing Team
  • Supply Team
  • Go-to-market Team
  • Switch strategy
  • Switch strategy learnings

Drivers & barriers of switch

  • Switch - Drivers
  • Switch - Barriers

Key switch markets

  • USA
  • UK
  • EU - EMA
  • Germany
  • France
  • New Zealand
  • Australia
  • Japan
  • Brazil
  • OTC reimbursement can deter sales

Switch pipeline

  • Switch pipeline overview
  • USA switch forecasts
  • US switch difficult but rewarding PDE5i switches for ED treatment
  • PDE5i sales forecast; leading markets
  • Access to DOC in West behind Asia
  • DOC sales forecast; leading markets
  • Triptan switch has potential in US
  • Other CHC areas to watch
  • CBD - a high potential molecule

Key market switch mechanisms

  • Switch can occur under several models
  • USA switch mechanism
  • UK switch mechanism
  • EU Centralised Procedure switch mechanism
  • New Zealand switch mechanism
  • Australia switch mechanism
  • Japan switch mechanism
  • Brazil switch mechanism
  • OTC exclusivity incentivises switch
  • Inadequate exclusivity periods
  • Switch without exclusivity
  • Reclassifying via scheduling
  • Under-the-counter sales
  • Counterfeit medicines

Cost vs benefit

  • Cost vs benefit
  • Case study: Flonase

Consumers rapidly adopt digital tools

  • Digital benefits the healthcare cycle
  • Consumers already gathering data
  • Health demands from wearables
  • Digital consumer conversations
  • Smartspeaker engagement
  • Interactive audio ads in action
  • Tech innovation for self-care
  • Switching to digital data collection
  • Telehealth booms in pandemic

Test & trace

  • Increased capabilities to remotely test
  • Pros and cons of digital testing
  • Digital test and treat in action
  • Digital testing developments

Marketing learnings

  • Marketing learnings overview
  • Insights from marketing learnings
  • Marketing tactics overview
  • Failed switches
  • Switch successes

Key switches

  • Leading global switches
  • Top 10 global switches
  • Switches are leading brands globally
  • US dominates switch success
  • Top 10 US switches
  • ellaOne (HRA Pharma)
  • Flonase (GSK)
  • Nexium 24HR / Control (GSK)
  • Viagra Connect (Viatris)
  • Sildenafil switch first global in NZ
  • Poland first to switch sildenafil in Europe
  • ED switches on global scale low
  • Alli (GSK)
  • Zocor Heart-Pro (J&J)
  • Flomax (BI; now Sanofi)
  • Oxytrol for Women (Merck / MSD; then Bayer)
  • Voltaren Arthritis Pain (GSK)
  • Pataday (Alcon)

APPENDIX

The public health case

  • QALY loss as a result of pandemic
  • Mental health issues increasing

Reverse switch & restrictions

  • Factors influencing reverse switch
  • Addiction cardio and overdose risks
  • Health risks driven by misuse
  • Reverse switch case study: France
  • Global: restrictions not always effective
  • Steps to be taken by manufacturers

Sources Appendix